REGISTRATION

SPONSORSHIP OPPORTUNITIES

OPPORTUNITY TO OBTAIN CME CREDITS

AMP Europe 2024 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 12.5 UEMS EACCME credits.
Learn more about UEMS EACCME accreditation: https://www.uems.eu/areas-of-expertise/cme-cpd/eaccme

Who will be there?

  • Pathologist
  • Neuropathologist
  • Oncologist
  • Genetics
  • Biological Scientist
  • Laboratory Technologist
  • Pharmacologist
  • Toxicologist
  • Immunologist
  • Cell Biologist
  • Virologist
  • Surgeon
  • Molecular Genomics

REASONS TO ATTEND AMP EUROPE 2024

Access early results

Position yourself for success

Find answers to your questions

Obtain cutting-edge insights

Connect and network

More about the venue

The Meliá Avenida America is a 4-star hotel that boasts a strategic location and is the ideal meeting space for AMP Europe 2024. 


Address

Juan Ignacio Luca de Tena Street, 36, Madrid


Distances

  • 6 km from Adolfo Suárez-Madrid Barajas Airport
  • 9 km from Atocha Railway Station
  • 9 km from Madrid Center

Get Access to our latest news

Stay connected with all of the latest updates by signing up to the mailing list.

Subscribe to our regular email newsletter and receive the latest AMP 2024 updates straight to your inbox.

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our websiteMCI Group collects your personal data to submit information related to AMP 2024. For more information, see our privacy statement.

A MESSAGE FROM THE ORGANIZING COMMITTEE CHAIR

We are excited to invite you to attend the Association for Molecular Pathology (AMP) 2024 Europe Congress, which will take place June 24-26, 2024 in Madrid, Spain.

AMP is the leading organization in the field of molecular diagnostics, and our Europe Congress is a premier meeting of molecular professionals around the globe. As always, we will explore how cutting-edge technology and developments in molecular testing and diagnostics continue to have a major impact on patient care. Please be sure to check back for all the latest information.

We look forward to seeing you in Madrid in June 2024!

Graf Erin Photo

Chair

Erin H. Graf, PhD
Phoenix, AZ, USA
Mayo Clinic

300+ Attendees

30+ Sessions

Scientific
Program

Area

Networking
Events

ORGANIZING COMMITTEE

Graf Erin Photo

Chair

Erin H. Graf, PhD
Phoenix, AZ, USA
Mayo Clinic

Mafouz RamiPhoto

Vice-Chair

Rami Mafouz, MD, MPH
Beirut, Lebanon
American University of Beirut Medical Center

Monzon Frederico Photo

Committee - Genetics

Frederico Monzon, MD
Houston, TX, USA
Genomic Path

Mroz Pawel Photo

Committee - HemePath

Pawel Mroz, MD, PhD
Minneapolis, MN, USA
University of Minnesota

Leon Annette Photo

Committee - Informatics

Annette Leon, PhD
Oakland, NC, USA
Fabric Genomics

Committee - Solid Tumors Tejus A. Bale , MD, PhD

Committee - Solid Tumors

Tejus A. Bale , MD, PhD
New York, NY, USA
Memorial Sloan Kettering Cancer Center

GET TO KNOW THE ASSOCIATION FOR MOLECULAR PATHOLOGY

The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics.

AMP’s 2,900+ members include individuals from academic and community medical centers, government, and industry; including pathologist and doctoral scientist laboratory directors; basic and translational scientists; technologists; and trainees.

To learn more about AMP, please visit: https://www.amp.org/about/who-we-are/

members
+ 0

Federico Monzon

Federico A. Monzon is a molecular pathologist with extensive experience translating novel genomic technologies into clinical molecular tests, including leading studies on prostate and renal cancer genomics and the validation of one of the first FDA-cleared gene expression clinical assays for the diagnosis of tumors of unknown origin while at the University of Pittsburgh and Houston Methodist Hospital. At Invitae and Baylor Genetics laboratories, he pioneered the use of panel testing for hereditary cancers as well as cancer exome sequencing.

Dr. Monzon is a consultant on medical and scientific strategy for companies in the diagnostic space. Currently, he is Chief Medical Officer (CMO) at Delphi Diagnostics, a laboratory focused on providing genomic tools for the management of breast cancer patients. Prior to that, he served as CMP for Castle Diagnostics and served as Medical Director of Oncology and Medical Director for Latin America at Invitae Corporation. Previously, Dr. Monzon served as Director of Pathology at the Cancer Genetics Laboratory at Baylor College of Medicine. He earned his M.D. from the Universidad Nacional Autónoma de México (UNAM) and is board-certified by the American Board of Pathology in anatomic, clinical and molecular genetic pathology. Dr Monzon was the 2017 President of the Association for Molecular Pathology (AMP) and continues to be engaged in AMP and other professional societies to shape the future of clinical genomic medicine.

Soon!